- Global Pharma News & Resources

DFE Pharma researcher recognized as one of the 2021 Outstanding Early Career Scientists

Alberto Berardi, Product Application Specialist at DFE Pharma awarded prestigious industry accolade



Goch, Germany (6th December 2021) – DFE Pharma Product Application Specialist, Alberto Berardi, has been recognized as one of the 2021 Outstanding Early Career Scientists by the editors of the Journal of Pharmaceutical Sciences and the American Pharmacists’ Association1. These awards acknowledged outstanding early career scientists for publishing their most original and significant scientific findings.


Berardi’s recognition came from his article which focused on superdisintegrants. Within a formulation these are often not interchangeable and thus appropriate selection is key for effective disintegration performance. Specifically, he showed in the study that in a hydrophobic matrix tablet formulation, croscarmellose sodium and sodium starch glycolate could still provide rapid disintegration upon harsh storage conditions, while crospovidone could not. The study was recognized by the JPharmSci® editors as one of the six-monthly featured articles in the May issue.


“I am very proud of this recognition received by our colleague Alberto Berardi. His award is a great example of how at DFE Pharma we strive to offer, not only premium quality excipients, but also expert services and key insights to our customers” comments Bas van Driel, CEO of DFE Pharma, “Together with our portfolio, our expertise and knowledge base enables us to support (bio)pharmaceutical companies in their success towards a healthier world”.


Berardi holds a master’s degree in Pharmacy from the University of Camerino (Italy) and a PhD in Pharmaceutical Technology from the University of East Anglia (UK).  Before joining DFE Pharma, he worked in academia as associate professor in pharmaceutical technology in Jordan. Berardi has 28 scientific publications in journals in the field of pharmaceutical technology and drug delivery. His area of expertise is on Oral Solid Dose (OSD) with particular focus on superdisintegrants and he is now a Product Application Specialist in OSD at DFE Pharma.


These awards recognize scientists who were the primary authors of articles and were either graduate students or within their first 10 years post-Ph.D. in a permanent appointment (such as an academic, foundation, government, or industrial scientist position) to bring further attention to their scientific research and achievements.






  1. Journal of Pharmaceutical Sciences. 2021 Outstanding Early Career Scientists. DOI:



About DFE Pharma


DFE Pharma is a global leader in pharmaceutical excipient solutions. We strive to develop, produce and supply the highest quality functional excipients for use in the pharmaceutical, biopharmaceutical and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations.


Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients for release in a predictable and effective manner into the patient’s system. With over a century of experience and over 400+ people worldwide in over 100 countries serving over 5,000 customers, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies in their journey to improve patients’ lives. We are driven by our purpose your medicines, our solutions. Moving to a healthier world.


Learn more at or follow us on LinkedIn




Media Contact:

Amanda Leweson - Discovery PR, on behalf of DFE Pharma 


Mobile: + 44 (0) 7852 153 791  

Office:   +44 (0) 1606 889 194  

Editor Details

Related Links

Last Updated: 07-Dec-2021